ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company

201-500US

About ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company

ImClone Systems is a fully integrated global biopharmaceutical company committed to advancing oncology care by developing and commercializing a portfolio of targeted biologic treatments designed to address the medical needs of patients with a variety of cancers. On November 24, 2008, ImClone Systems became a wholly-owned subsidiary of Eli Lilly and Company (NYSE: LLY).

ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company

About ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company

Open Positions(88)

Analyst-Tech@Lilly MES

Associate Vice President - Chief Financial Officer (CFO), LillyDirect

Customer Expansion Strategy

Quality Intern

Therapy Area Specialist / Senior Therapy Area Specialist – Oncology

Engineer-EG Process

2026 Tech Internship – Hyderabad

IAM SecOps Engineer - PKI & Encryption

Operations Associate Formulation and Material Preparation (m/w/d)

Associate Director – Quality Assurance - Operational Readiness

Associate Director - Medical Science Liaison (Cardiometabolic) - Nashville, TN

Associate Director - Capital Projects Procurement Leader

Software Engineer - Fixed Duration

Director, Global Regulatory Affairs - Chemistry, Manufacturing and Controls (CMC), Platform Innovation - Biologics

Scientist - LEM

Scientist - Analytical Method Development SMDD Foundry Readiness

Senior Director - Counsel, Clinical Development, Regulatory Legal

Electrician C – Maintenance – IAPI

Reference Standard Manufacturing Scientist - BRD Corporate Reference Standards Organization (CRSO)

Supply Chain Associate - API EM

Supervisor - Parenteral Manufacturing Operations 2nd Shift

Maintenance Technician

Supervisor - Parenteral Manufacturing Operations 1st Shift

Supervisor - Parenteral Manufacturing Operations 3rd Shift

Lead - Parenteral Manufacturing Operations